Reported 2 days ago
UBS has reaffirmed its 'Buy' rating for Elevance Health (ELV), citing promising stability and growth prospects following the company's second-quarter results, which showed adjusted earnings per share of $8.84 and revenues of $49.8 billion, surpassing expectations. However, Elevance has adjusted its earnings outlook lower and raised its medical loss ratio expectations due to unfavorable cost trends in its Affordable Care Act and Medicaid segments. Despite this, UBS remains optimistic about earnings stability in its commercial and Carelon sectors.
Source: YAHOO